September 1, 2026
Research
Omega-3 and Mood: What the Trials Actually Found
September 2, 2026 · 8 min read
Eighteen thousand adults took a fish oil capsule every day for five years, and their mood scores did not move. The mean difference against placebo was 0.03 points.
That is VITAL-DEP, the largest randomised trial ever run on this question. Any honest piece about omega-3 and mood has to start there.
It is not the whole picture. Prevention and treatment are separate questions, and they have separate answers. But the flat result is the right anchor, because it is the one most articles leave out.
The largest trial came back flat
VITAL-DEP randomised 18,353 US adults aged 50 and over. Half took 1 g a day of marine omega-3 — 465 mg EPA and 375 mg DHA. Half took a matching placebo. Median follow-up was 5.3 years.
The omega-3 arm logged 651 depression events, or 13.9 per 1,000 person-years. Placebo logged 583, or 12.3. The hazard ratio came out at 1.13 (95% CI 1.01–1.26).
That is the wrong direction, just inside statistical significance. The authors were careful not to over-read it, and so should you.
Mood scores told a quieter story. The mean difference in PHQ-8 change was 0.03 points on a scale running 0 to 24.
Key Study: Five Years, No Movement
VITAL-DEP randomised 18,353 adults aged 50+ to 1 g/day of marine omega-3 (465 mg EPA, 375 mg DHA) or placebo for a median 5.3 years. Risk of depression or clinically relevant depressive symptoms: hazard ratio 1.13 (95% CI 1.01–1.26). Change in PHQ-8 mood score: mean difference 0.03 points (95% CI −0.01 to 0.07).
Source: Okereke et al., JAMA, 2021 (n=18,353).
So at a supermarket dose, over five years, in people who were well at the start, nothing useful happened. Treat that as your default expectation.
Thirty-one trials in 41,470 people agree
A 2021 systematic review in the British Journal of Psychiatry pooled every trial of at least 24 weeks. It found 31 trials of long-chain omega-3 covering 41,470 participants.
The pooled risk ratio for depressive symptoms was 1.01 (95% CI 0.92–1.10). Median dose was 0.95 g a day over 12 months. The authors graded it moderate-quality evidence.
The interesting number is the heterogeneity. I² came out at 0%, meaning the trials did not disagree with each other at all.
Thirty-one trials agreeing on nothing is about as settled as nutrition research gets. For lowering the risk of low mood in people who do not currently have it, omega-3 is not the lever.
The Cochrane effect is real and smaller than it looks
Now the other question. What about people already carrying a diagnosis?
The 2021 Cochrane review pooled 33 placebo-controlled trials in 1,848 participants. The standardised mean difference was −0.40 (95% CI −0.64 to −0.16), favouring omega-3.
An SMD of 0.40 sounds respectable. Cochrane did the translation: it equates to roughly 2.5 points on the 17-item Hamilton scale, with a confidence interval of 1.0 to 4.0 points.
The minimum change on that scale considered clinically meaningful is 3.0 points. The central estimate sits below it.
The secondary outcomes were flatter still. Remission rates gave an odds ratio of 1.13 (95% CI 0.74–1.72) across 8 studies in 609 people. Response rates gave 1.20 (0.80–1.79) across 17 studies in 794 people. Neither cleared significance.
Cochrane graded the whole thing very low certainty and flagged funnel plot asymmetry, which is the signature of small positive trials being published while small null ones are not. If you want the mechanics of why that matters, we covered it in what a p-value actually tells you.
EPA carries the signal; DHA does not
This is the part worth knowing before you buy anything.
A 2019 meta-analysis in Translational Psychiatry pooled 26 double-blind trials in 2,160 participants. The overall effect was an SMD of −0.28.
Then the authors split by formulation. EPA-pure preparations returned an SMD of −0.50. EPA-major preparations, meaning at least 60% EPA, returned −1.03 at doses up to 1 g of EPA a day.
DHA-pure and DHA-major preparations returned no benefit at all.
A 2023 review in Prostaglandins, Leukotrienes and Essential Fatty Acids reached the same place from different trials. Across 10 studies in 1,426 people, only interventions with EPA at 60% or more of total EPA plus DHA moved the needle, at an SMD of −0.36 (95% CI −0.68 to −0.05).
Key Study: Formulation Beats Dose
Pooling 26 randomised placebo-controlled trials in 2,160 participants, omega-3 produced an overall SMD of −0.28 on depressive symptoms. Split by formulation, EPA-pure gave −0.50 and EPA-major (≥60% EPA) gave −1.03 at ≤1 g EPA daily. DHA-pure and DHA-major preparations showed no benefit.
Source: Liao et al., Translational Psychiatry, 2019 (26 trials, n=2,160).
If mood is your stated reason for taking an omega-3, a DHA-weighted oil is not the one the trials tested. Our own algal oil is DHA-led, and we would rather say that plainly than let you infer otherwise. For what each fatty acid actually does, DHA vs EPA sets out the difference.
The dose ladder, and where it stops climbing
The 2023 review split its trials by EPA dose. The pattern is not the one supplement marketing would predict.
Between 1 g and 2 g of EPA a day, the pooled SMD was −0.43 (95% CI −0.79 to −0.07). At 2 g a day or more, it fell to −0.20 (95% CI −0.48 to 0.07) and lost significance.
More was not better. Heterogeneity ran at 86–88% across those bands, so the trials disagreed sharply with each other.
The International Society for Nutritional Psychiatry Research published practice guidelines in 2019. Its recommendation is 1 to 2 g of net EPA daily, from pure EPA or from a formula with an EPA to DHA ratio above 2:1.
The same guidelines are explicit that this sits alongside standard care rather than replacing it. That framing is the guideline authors' own, and it is the right one.
If your mood has been low for more than a couple of weeks, that is a GP conversation. Nothing in this article is a reason to delay one. Omega-3 appears in the guidelines as an adjunct, and the effect sizes above are exactly why.
What a UK label is allowed to say
Two authorised claims exist for these fatty acids on the GB Nutrition and Health Claims Register. DHA at 250 mg a day contributes to the maintenance of normal brain function. EPA and DHA together at 250 mg a day contribute to normal heart function.
That is the complete list. There is no authorised claim for mood, emotional wellbeing, or anything adjacent.
The wording matters too. "Maintenance of normal brain function" is a maintenance claim, not an improvement claim. It says the nutrient keeps a working system working.
So when a fish oil box carries mood language, it is telling you about the marketing department rather than the register. That is a useful filter, and it costs nothing to apply.
Food first, and the arithmetic is unforgiving
The NHS advises at least two portions of fish a week, one of them oily. A portion is around 140 g.
Hit that reliably and you are doing better than most UK adults. You are still nowhere near the 1 to 2 g of EPA a day the positive trials used.
That gap is the honest case for a supplement, and it is a narrower case than it first appears. Getting to a gram of EPA daily from capsules means reading the back of the box, not the front.
We worked the dose arithmetic out in full in omega-3 after 50, including why a "1,000 mg fish oil" capsule usually carries about 300 mg of combined EPA and DHA.
Work out what you already eat. Then decide what number you are trying to reach, and whether mood is really the reason.
What this means if you are 55 and generally well
Expect nothing on mood from a standard capsule. That is what 41,470 people across 31 trials came back with, and one 18,353-person trial confirmed over five years.
If you take omega-3, take it for the reasons that hold up: the authorised heart and brain-function claims, the triglyceride response at higher doses, and a diet short on oily fish.
If you are specifically interested in the mood literature, the useful version of the question is narrow. It concerns people with a diagnosis, taking 1 to 2 g of EPA, alongside whatever their clinician has already recommended. Even there, the pooled effect sits under the threshold for a change worth noticing.
We sell an omega-3 product and we are telling you the mood evidence is thin. That is not modesty. It is the only position that survives reading the papers, and you would find out anyway.
Buy it for the heart and brain-function claims, or for a diet with no fish in it. Not for how you feel on a Tuesday.
References
- Okereke OI, Vyas CM, Mischoulon D, et al. (2021). "Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial." JAMA, 326(23), 2385-2394. PMID: 34932079
- Appleton KM, Voyias PD, Sallis HM, et al. (2021). "Omega-3 fatty acids for depression in adults." Cochrane Database of Systematic Reviews, Issue 11, CD004692. DOI: 10.1002/14651858.CD004692.pub5
- Deane KHO, Jimoh OF, Biswas P, et al. (2021). "Omega-3 and polyunsaturated fat for prevention of depression and anxiety symptoms: systematic review and meta-analysis of randomised trials." British Journal of Psychiatry, 218(3), 135-142. PMID: 31647041
- Liao Y, Xie B, Zhang H, et al. (2019). "Efficacy of omega-3 PUFAs in depression: A meta-analysis." Translational Psychiatry, 9, 190. DOI: 10.1038/s41398-019-0515-5
- Kelaiditis CF, Gibson EL, Dyall SC (2023). "Effects of long-chain omega-3 polyunsaturated fatty acids on reducing anxiety and/or depression in adults; A systematic review and meta-analysis of randomised controlled trials." Prostaglandins, Leukotrienes and Essential Fatty Acids, 192, 102572. PMID: 37028202
- Guu TW, Mischoulon D, Sarris J, et al. (2019). "International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder." Psychotherapy and Psychosomatics, 88(5), 263-273. PMID: 31480057
- NHS (2026). "Fish and shellfish." NHS Live Well, Eat Well.
- Department of Health and Social Care (2026). "GB Nutrition and Health Claims Register." Authorised claims for DHA (250 mg/day, maintenance of normal brain function) and EPA plus DHA (250 mg/day, normal function of the heart), retained from Commission Regulation (EU) No 432/2012.
Continue Reading
August 18, 2026